U.S. markets closed

Sinopharm Group Co., Ltd. (SHTDY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
14.39-0.76 (-5.02%)
At close: 3:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.15
Bid0.00 x 0
Ask0.00 x 0
Day's Range14.37 - 14.65
52 Week Range10.20 - 18.30
Avg. Volume32,971
Market Cap9.019B
Beta (5Y Monthly)N/A
PE Ratio (TTM)7.57
EPS (TTM)1.90
Earnings DateN/A
Forward Dividend & Yield0.53 (3.56%)
Ex-Dividend DateJun 14, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    Boyu, Sinopharm among bidders shortlisted for Mundipharma China -sources

    Drugmaker Mundipharma has included Boyu Capital and state-owned Sinopharm on a shortlist of bidders for its Chinese business, two people familiar with the situation said. Chinese buyout firms CITIC Capital and CPE are also on the shortlist for Mundipharma's China unit, which sources have said could fetch more than $1 billion.

  • Reuters

    CORRECTED-(OFFICIAL)-UAE, Bahrain make Pfizer/BioNTech shot available to those who got Sinopharm vaccine

    The United Arab Emirates and Bahrain have made the Pfizer/BioNTech coronavirus vaccine available as a booster shot to those initially immunised with a vaccine developed by the China National Pharmaceutical Group (Sinopharm). The Gulf states, which have vaccinated large portions of their populations, initially started inoculating residents and citizens with the Sinopharm COVID-19 shot before later introducing other vaccines.

  • Sinopharm's two vaccines show more than 72% efficacy against Covid-19, says U.S. medical journal

    Sinopharm's two vaccines show more than 72% efficacy against Covid-19, says U.S. medical journal

    Two COVID-19 vaccines from China's state-run Sinopharm have shown more than 70% efficacy against symptomatic cases, according to the first detailed results of a large late-stage study. The two inactivated vaccines developed by China National Biotec Group, a subsidiary of Sinopharm , were found to be 72.8% and 78.1% effective against symptomatic COVID-19, based on findings from the Phase 3 trial. The peer-reviewed study were published in the Journal of the American Medical Association on May 26. The results combined findings from trials in the United Arab Emirates, Bahrain, Egypt and Jordan including a total of 40,832 volunteers. Earlier this month, the World Health Organization granted emergency use authorization for the Sinopharm vaccine.